{"version":"1.0","type":"rich","provider_name":"techandbusiness.org","provider_url":"https://techandbusiness.org","title":"Ocugen changes primary measure in Phase 3 OCU400 trial","author_name":"techandbusiness.org · Tech & Business","thumbnail_url":"https://www.newscase.com/wp-content/uploads/ai-imgs/US67577C1053-2026-10-20-04-51-08.png","width":600,"height":400,"html":"<blockquote class=\"tb-newswire-embed\" style=\"max-width:600px;border-left:3px solid #22d3ee;padding:12px 16px;margin:0;font-family:-apple-system,system-ui,sans-serif;background:#09090b;border-radius:0 8px 8px 0;\">\n      <p style=\"margin:0 0 8px;font-size:10px;font-weight:600;letter-spacing:0.1em;color:#71717a;\">techandbusiness.org · Tech & Business</p>\n      <p style=\"margin:0 0 8px;font-size:18px;font-weight:700;line-height:1.3;color:#fff;\"><a href=\"https://techandbusiness.org/newswire/qN_IaI4IuvuIr8GIA7JIlP\" style=\"color:#fff;text-decoration:none;\">Ocugen changes primary measure in Phase 3 OCU400 trial</a></p>\n      <p style=\"margin:0;font-size:14px;color:#a1a1aa;line-height:1.5;\">Ocugen has changed the primary outcome measure for its pivotal Phase 3 OCU400 gene therapy trial from MLMT to LDNA, newscase reported, citing an investor presentation carried in an SEC filing. The com...</p>\n    </blockquote>"}